Last reviewed · How we verify

probiotic ® pur

Yuzuncu Yil University · Phase 3 active Small molecule

Probiotic PUR restores beneficial gut microbiota to improve intestinal barrier function and modulate immune responses.

Probiotic PUR restores beneficial gut microbiota to improve intestinal barrier function and modulate immune responses. Used for Gastrointestinal disorders associated with dysbiosis.

At a glance

Generic nameprobiotic ® pur
SponsorYuzuncu Yil University
Drug classProbiotic
ModalitySmall molecule
Therapeutic areaGastroenterology / Immunology
PhasePhase 3

Mechanism of action

This probiotic formulation contains live beneficial bacteria that colonize the gastrointestinal tract, enhancing the intestinal epithelial barrier, reducing pathogenic bacterial overgrowth, and promoting a balanced microbiome. By restoring eubiotic conditions, it may enhance mucosal immunity and reduce systemic inflammation through microbial metabolite production and immune tolerance mechanisms.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: